IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: LI et al.

Examiner: To Be Assigned

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed:

Herewith

Title:

METHOD FOR ASSAYING COMPOUNDS THAT DECREASE THE ACTIVITY OF POLY(APP-RIBOSE)-POLYMERASE (PARP)

POWER OF ATTORNEY FOR PATENT APPLICATION

Mail Stop Patent Applications Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

I, <u>Ross J. Oehler</u>, an Officer of Aventis Pharmaceuticals Inc., Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer No.: 005487

By:

Røss J. Oehler

Title:

Assistant, Secretary

Date:

Address correspondence and telephone calls to:

William C. Coppola, Reg. No. 41,686

Aventis Pharmaceuticals Inc.

Patent Department

Route #202-206 / P.O. Box 6800

Bridgewater, New Jersey 08807-0800

Telephone (908) 231-3800

Telefax

(908) 231-2626

DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s). I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD FOR ASSAYING	G COMPOUNDS THAT DECREASE THE ACTIVITY OF
POLY(A	DP-RIBOSE)-POLYMERASE (PARP)

	and the specification of (check one)	☐ v a	is attached hereto (Aventis Docket No. USAV2002/0121USNP) was filed on as U.S. Application Number and was amended on (if applicable). was described and claimed in PCT Int'l Application Number filed on and as amended under PCT Article 19 on (if any).		
	including the claims as a	amended by ar lutv to disclose	eviewed and understand the contents of the above identified specification, ny amendment referred to above. The to the U.S. Patent and Trademark Office all information known to me/us to in 37 C.F.R. 1.56.		
	I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:				
Foreign	0301628.4	GB	24/04/2002		
Priority:	Number	Country	24/01/2003 Day/Month/Year Filed		
Prior					
Foreign Appln(s):	Number	Country	Day/Month/Year Filed		
\boxtimes	I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below:				
	60/412,136 Number	09/19/2002 Filing Date	2		
	I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filling date of the prior application and the national or PCT international filing date of this application.				
	Application Serial No.	Filing Date	Status (Patented, Pending)		
and the like	so made are punishable t	nurtner that the	of my own knowledge are true and that all statements made on information lesse statements were made with the knowledge that willful false statements isonment, or both, under Title 18, United States code §1001, and that such the application or any patent issued thereon.		
Inventors(s):	Additional names	s and signature	es are attached.		
1. Full name: <u>Z</u>	huyin Julie LI		2. Full name: Shujaath MEHDI		
Signature:			Simatura		
Signature: . Date: .			Signature: Date:		
Country of Citizenship: United States			Country of Citizenship: United States		
Residence: Flemington, New Jersey (City and State/City and Country only)			Residence: Manville, New Jersev		
			· · · · · · · · · · · · · · · · · · ·		
P. O. Address: 12 Hastings Place Flemington, NJ 08822			P. O. Address: 43 North 14 th Avenue, Apt. 2		

3. Full name:	— 4. Full name:
Signature:	Signature:
Date:	Date:
Country of Citizenship:	Country of Citizenship:
Residence:(City and State/City and Country only)	Residence:
P. O. Address:	P. O. Address:
5. Full name:	6. Full name:
Signature:	Signature:
Date:	
Country of Citizenship:	Date: Country of Citizenship:
Residence:	Residence:
Residence:(City and State/City and Country only)	(City and State/City and Country only)
P. O. Address:	

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-3800
Telefax (908) 231-2626

Aventis Docket No. USAV2002/0121USNP